A randomized, controlled trial of the medtronic Endeavor drug-eluting coronary stent system versus the taxus paclitaxel-eluting coronary stent system in de novo native coronary artery lesions.

Trial Profile

A randomized, controlled trial of the medtronic Endeavor drug-eluting coronary stent system versus the taxus paclitaxel-eluting coronary stent system in de novo native coronary artery lesions.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 19 Apr 2012

At a glance

  • Drugs Paclitaxel; Zotarolimus
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia; Restenosis
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms ENDEAVOR-IV
  • Most Recent Events

    • 19 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Nov 2011 Final five-year results presented at the 23rd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics, according to a Medtronic media release.
    • 07 Nov 2011 Results presented at the 23rd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top